stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
49.25
4.46
+9.96%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Gross margin
Enliven Therapeutics, Inc.'s gross margin over the twelve months to 30 September 2022 was 0.00%. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2022 | 0.00% | 0.00 |
| Jun 2022 | 0.00% | 0.00 |
| Mar 2022 | 0.00% | 0.00 |
| Dec 2021 | 0.00% | 0.00 |
| 8 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| VRDN Viridian Therapeutics, Inc. compare | 100.0% |
| DNLI Denali Therapeutics Inc. compare | 98.7% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 93.2% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 90.5% |
| ELVN Enliven Therapeutics, Inc. | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue